Colorectal cancer (CRC) caused nearly 204,000 deaths in Europe in 2004. Despite recent advances in the treatment of advanced disease, which include the incorporation of two new cytotoxic agents irinotecan and oxaliplatin into first-line regimens, the concept of planned sequential therapy involving three active agents during the course of a patient's treatment and the integrated use of targeted monoclonal antibodies, the 5-year survival rates for patients with advanced CRC remain unacceptably low. For patients with colorectal liver metastases, liver resection offers the only potential for cure. This review, based on the outcomes of a meeting of European experts (surgeons and medical oncologists), considers the current treatment strategies available to patients with CRC liver metastases, the criteria for the selection of those patients most likely to benefit and suggests where future progress may occur.

The management of colorectal liver metastases : Expanding the role of hepatic resection in the age of multimodal therapy / A.C. Chiappa, M. Makuuchi, N.J. Lygidakis, A. P. Zbar, G. Chong, E. Bertani, P.J. Sitzler, R. Biffi, U. Pace, P.P. Bianchi, G. Contino, P. Misitano, F. Orsi, L. Travaini, G. Trifirò, M. G. Zampino, N. Fazio, A. Goldhirsch, B.G. Andreoni. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 72:1(2009 Oct), pp. 65-75. [10.1016/j.critrevonc.2008.11.003]

The management of colorectal liver metastases : Expanding the role of hepatic resection in the age of multimodal therapy

A.C. Chiappa
Primo
;
P.P. Bianchi;B.G. Andreoni
Ultimo
2009

Abstract

Colorectal cancer (CRC) caused nearly 204,000 deaths in Europe in 2004. Despite recent advances in the treatment of advanced disease, which include the incorporation of two new cytotoxic agents irinotecan and oxaliplatin into first-line regimens, the concept of planned sequential therapy involving three active agents during the course of a patient's treatment and the integrated use of targeted monoclonal antibodies, the 5-year survival rates for patients with advanced CRC remain unacceptably low. For patients with colorectal liver metastases, liver resection offers the only potential for cure. This review, based on the outcomes of a meeting of European experts (surgeons and medical oncologists), considers the current treatment strategies available to patients with CRC liver metastases, the criteria for the selection of those patients most likely to benefit and suggests where future progress may occur.
Colorectal cancer; Disease-free survival; Hepatic metastases; Neoadjuvant therapy; Surgery; Survival
Settore MED/18 - Chirurgia Generale
ott-2009
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/171728
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 22
social impact